Selank: A Literature Course on What the Published Research Reports

Selank is a short synthetic peptide that has been studied almost entirely in laboratory settings, with a research record concentrated in Russian-language and Russian-affiliated journals. This course walks through six modules: what Selank is, the mechanisms researchers have described, the outcomes reported study by study, what the published record contains on adverse events, what is known about pharmacokinetics, and how the compound sits in regulatory terms. Each module closes with the limits of the underlying evidence.

This page is for educational purposes only and is not medical advice; consult a licensed physician before acting on any health information. No numerical doses, durations or protocols are stated here, because the verified papers summarised on this page do not supply figures that could be restated accurately, and a figure that cannot be sourced is omitted rather than paraphrased.

Module 1: What Selank Is and How It Has Been Studied

Definition and class

Selank is a synthetic peptide repeatedly described in study titles as an analogue of tuftsin, an endogenous immunoactive tetrapeptide; that description was used, for example, in a rat morphine-withdrawal report (PMID 36322304) and in a rat ethanol-and-memory report (PMID 31625062). In clinical psychiatry literature it has been characterised as a peptide anxiolytic investigated in generalised anxiety disorder and neurasthenia (PMID 18454096). Functionally, then, the literature places Selank in the category of regulatory peptides derived from or modelled on endogenous immune-active sequences, rather than in the benzodiazepine, SSRI or classical small-molecule classes.

Origin and research setting

The published clinical work on Selank appeared in Russian psychiatric and neurological journals, including a report on efficacy and possible mechanisms in generalised anxiety disorders and neurasthenia (PMID 18454096) and a later paper on optimising the treatment of anxiety disorders with selank (PMID 26356395). The preclinical record is broader and includes rodent behavioural models, organ-level histology and cell-culture experiments.

Forms studied

The verified literature describes several experimental formats rather than consumer formats: whole-animal administration in rats under stress and withdrawal conditions, isolated tissue work such as recordings from hippocampal CA1 neurons (PMID 28361410), and human-derived cell culture using the IMR-32 neuroblastoma line alongside GABA and olanzapine (PMID 28293190). A network-level analysis compared Selank and Semax using a functional connectomic approach (PMID 32342318).

Limits of the evidence in Module 1: the verified papers identify the compound and its research contexts, but they do not constitute a chemistry or manufacturing review, do not compare formulations, and do not establish that findings in one experimental form transfer to another.

Module 2: Mechanism as Described in the Literature

Mechanistic work on Selank has clustered around a few themes. The most repeated is GABAergic signalling. One in vivo study reported that Selank administration affected the expression of some genes involved in GABAergic neurotransmission (PMID 26924987). A companion cell-culture study compared GABA, Selank and olanzapine and reported that all three affected the expression of genes involved in GABAergic neurotransmission in IMR-32 cells (PMID 28293190). These are transcript-level observations; they describe changes in gene expression, not a receptor binding profile.

A second theme is direct neuronal activity. Researchers examined the effect of Selank on spontaneous synaptic activity of rat hippocampal CA1 neurons, an electrophysiological endpoint that sits closer to network function than gene expression does (PMID 28361410).

A third theme is neurotrophic signalling. In a rat model of ethanol-induced memory impairment, the study framed Selank's action in terms of regulation of brain-derived neurotrophic factor content in the hippocampus and prefrontal cortex (PMID 31625062).

A fourth theme reflects the peptide's tuftsin ancestry: immune signalling. One report examined the influence of Selank on the level of cytokines under conditions of "social" stress (PMID 32621722), an endpoint that belongs to neuroimmune rather than classical neurotransmitter pharmacology.

Finally, interaction with an established anxiolytic has been examined. A behavioural study reported that Selank enhanced the effect of diazepam in reducing anxiety in rats under unpredictable chronic mild stress (PMID 28280289), a finding sometimes read as indirect support for a GABAergic mechanism but which, on its own, describes a behavioural interaction rather than a molecular one.

Limits of the evidence in Module 2: these mechanisms were described in separate experimental systems and were not integrated into a single validated pathway. Gene-expression changes, cytokine measurements and electrophysiological recordings are different levels of analysis, and the verified papers do not demonstrate that any one of them explains the behavioural observations reported elsewhere in the literature.

Module 3: Reported Outcomes by Study

The table below summarises the model, the endpoint and what each report described. It is a map of the literature, not a summary of effectiveness; none of these entries should be read as a benefit claim for any person.

Read together, the preclinical record leans heavily on stress-based rodent paradigms: chronic mild stress, foot-shock, restraint, social stress, ethanol exposure and opioid withdrawal. The clinical record in the verified list consists of two Russian-language psychiatric papers (PMID 18454096, PMID 26356395), which is a narrow foundation by the standards usually applied to psychotropic agents.

Limits of the evidence in Module 3: rodent stress models are screening tools, not miniature versions of human disorders. Sample sizes, blinding, randomisation and replication status are not restated here because the verified abstracts do not supply them consistently. No study in this list was a large, multi-site, placebo-controlled trial, and no reported outcome should be generalised to any individual.

Module 4: Selank Side Effects: What Studies Report

The most important observation in this module is structural: none of the verified papers was designed as a dedicated safety, toxicology or adverse-event study. The record summarised here reports mechanism and efficacy endpoints, so it cannot support statements about incidence of adverse effects, tolerability thresholds or long-term risk.

The closest organ-level endpoints in the verified list are hepatic. One study examined morphological parameters of rat liver under chronic foot-shock stress with Selank (PMID 31243679), and an earlier study examined the functional state of rat hepatocytes under restraint stress (PMID 28853100). Both were framed as investigations of Selank in stressed animals rather than as toxicity screens, and both measured tissue-level parameters in rats, not clinical safety outcomes in people.

On the immune side, the cytokine study under "social" stress conditions measured signalling molecules that can move in either direction depending on model and timing (PMID 32621722); researchers reported cytokine-level findings rather than adverse events.

The two clinical papers addressed efficacy and treatment optimisation in anxiety disorders and neurasthenia (PMID 18454096, PMID 26356395); this page does not reproduce a side-effect table from them because the verified abstract-level record does not provide one that could be quoted accurately.

Limits of the evidence in Module 4: absence of reported adverse events in a set of efficacy and mechanism papers is not evidence of safety. Without dedicated pharmacovigilance data, dose-ranging toxicology, or long-term human follow-up, the adverse-effect profile of Selank cannot be described from this literature.

Module 5: Pharmacokinetics Where Data Exist

Pharmacokinetics is the weakest area of the verified record. None of the papers listed on this page is a pharmacokinetic study. There is no absorption, distribution, metabolism or excretion dataset among them, no half-life estimate, no bioavailability comparison between routes, and no plasma or brain concentration-time curve that could be summarised.

What the literature offers instead is indirect: studies that administered Selank to animals and then measured downstream endpoints such as gene expression (PMID 26924987) or BDNF content in the hippocampus and prefrontal cortex (PMID 31625062). Central endpoints changing after peripheral administration is consistent with central engagement, but it is not a measurement of exposure and does not quantify how much peptide reached the brain or for how long.

Limits of the evidence in Module 5: because peptides are subject to rapid enzymatic degradation, exposure questions matter a great deal, and they are unanswered by the papers cited here. Any statement about duration of action, dosing intervals or route comparison would be unsupported by this evidence base and is therefore not made.

Module 6: Regulatory Status

Regulatory facts differ sharply by jurisdiction, and this section states them descriptively. Selank has no approved medicinal product in the United States: it has not been approved by the Food and Drug Administration for any indication, and it is not marketed there as a prescription drug. It likewise has no European Medicines Agency marketing authorisation. Its clinical investigation history, as reflected in the verified list, is Russian, with reports published in a Russian psychiatric and neurological journal (PMID 18454096, PMID 26356395).

In practice this means that material circulating outside approved channels is typically labelled "research use only" (RUO). An RUO label is a distribution category, not a quality guarantee and not an authorisation for human use; RUO material is not manufactured, tested or released under the standards applied to approved medicines.

On compounding: in the United States, compounding pharmacies operating under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act may generally use bulk substances that are FDA-approved drug components, the subject of an applicable USP or NF monograph, or included on the relevant FDA bulks lists. Peptides without approval, a monograph or bulks-list inclusion fall outside those pathways. Regulatory classifications change over time, and rules vary by country and by state. This page is informational and is not legal advice.

Limits of the evidence in Module 6: regulatory status is independent of scientific interest. Lack of approval does not mean a compound is unsafe, and publication in peer-reviewed journals does not mean a compound is approved or that its research findings have been independently verified.

What the Studies Did Not Test

A course on a thinly studied compound is most useful when it is explicit about absence. Based on the verified literature summarised here, the following were not tested:

• Long-term human safety. No study in this list followed people over extended periods or collected structured adverse-event data that this page could report.
• Pharmacokinetics in humans. No absorption, half-life, metabolism or route-comparison data appear in the verified record.
• Healthy-population outcomes. The preclinical work used stressed, ethanol-exposed or opioid-withdrawing animals (PMID 28280289, PMID 36322304); "enhancement" in healthy individuals was not an endpoint.
• Head-to-head clinical comparison. Although one cell study placed Selank alongside GABA and olanzapine (PMID 28293190) and one rat study examined it with diazepam (PMID 28280289), neither was a clinical comparative trial.
• Special populations. Pregnancy, paediatric use, hepatic or renal impairment and drug–drug interactions were not addressed in the verified papers.
• Independent replication at scale. Much of the record comes from a concentrated research community, and the connectomic analysis compared Selank with Semax as a methodological exercise (PMID 32342318) rather than confirming clinical outcomes.

Readers finishing this course should come away with a clear picture: Selank is a tuftsin-analogue peptide with a coherent but preliminary preclinical literature centred on GABAergic gene expression, synaptic activity, BDNF and cytokines, a small Russian clinical literature in anxiety disorders, no pharmacokinetic dataset in the verified record, no dedicated safety dataset, and no approved product in the United States or European Union.

References

• Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission (Frontiers in Pharmacology, 2016)
• GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells (Frontiers in Pharmacology, 2017)
• Effect of Selank on Spontaneous Synaptic Activity of Rat Hippocampal CA1 Neurons (Bulletin of Experimental Biology and Medicine, 2017)
• Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats (Behavioural Neurology, 2017)
• Effect of Selank on Functional State of Rat Hepatocytes under Conditions of Restraint Stress (Bulletin of Experimental Biology and Medicine, 2017)
• Effect of Selank on Morphological Parameters of Rat Liver in Chronic Foot-Shock Stress (Bulletin of Experimental Biology and Medicine, 2019)
• Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats (Bulletin of Experimental Biology and Medicine, 2019)
• Functional Connectomic Approach to Studying Selank and Semax Effects (Doklady Biological Sciences, 2020)
• The Influence of Selank on the Level of Cytokines Under the Conditions of "Social" Stress (Current Reviews in Clinical and Experimental Pharmacology, 2021)
• Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats (Bulletin of Experimental Biology and Medicine, 2022)
• Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia (Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 2008)
• Optimization of the treatment of anxiety disorders with selank (Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 2015)